Educational only — not medical advice.If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources.Under construction and review—see the updates log.
Typical dose range: Psychiatric off-label use generally starts low (often 25 mg nightly) and increases in weekly steps to reduce cognitive and paresthesia burden (clinical).
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30
Dosing & forms
Forms/strengths: Immediate-release tablets: 25 mg, 50 mg, 100 mg, 200 mg; sprinkle capsules exist (label/manufacturer-dependent).; Extended-release topiramate products exist (e.g., Trokendi XR, Qudexy XR) but are distinct formulations and not interchangeable without confirming equivalence (label/clinical).
Frequency: Psychiatric off-label use generally starts low (often 25 mg nightly) and increases in weekly steps to reduce cognitive and paresthesia burden (clinical).
Typical range: Psychiatric off-label use generally starts low (often 25 mg nightly) and increases in weekly steps to reduce cognitive and paresthesia burden (clinical).
Mechanism (brief)
Broad-mechanism antiepileptic and migraine-preventive agent (includes voltage-gated sodium-channel effects, enhanced GABA activity, AMPA/kainate antagonism, and carbonic anhydrase inhibition). In psychiatry it is sometimes used off label for alcohol use disorder, binge-eating disorder, and to mitigate antipsychotic-associated weight gain, balancing potential benefit against cognitive and metabolic adverse effects.
Metabolism & Half‑life
Metabolism: Not extensively metabolized; metabolites formed via hydroxylation, hydrolysis, and glucuronidation (label).